Patent classifications
C07D281/02
CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREOF
The present disclosure provides a compound having the structure: Formula (I) wherein R.sub.1 is —H or -(alkyl); R.sub.2 is -(alkyl)-CO2H or -(alkyl)-CO2-(alkyl); R.sub.3 is —H or -(alkyl); and X is —Br or —I, or a pharmaceutically acceptable salt or ester thereof, for treating or preventing a neurological disorder, including Huntington’s disease, Rett syndrome, and CDKL5 disorder.
CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREOF
The present disclosure provides a compound having the structure: Formula (I) or a pharmaceutically acceptable salt or ester thereof, for treating or preventing a neurological disorder, including Huntington's disease, Rett syndrome, and CDKL5 disorder.
CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREOF
The present disclosure provides a compound having the structure: Formula (I) or a pharmaceutically acceptable salt or ester thereof, for treating or preventing a neurological disorder, including Huntington's disease, Rett syndrome, and CDKL5 disorder.
S-OXIDES OF 2,3-DIARYL-2,3-DIHYDRO-4H-1,3-THIAZIN-4-ONES AND 2,3-DIARYL-1,3-THIAZEPAN-4-ONES AND METHODS FOR MAKING
A compound with the following general formula and a general method of making this compound are provided: R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.12, R.sup.13 and R.sup.14 are each independently selected from the group that includes hydrogen, halogen, nitro, cyano, amido, pyridyl, alkyl, aryl, alkoxy, cycloalkyl, heteroalkyl, heterocyclyl, aralkyl, heteroaryl and heteroaralkyl.
##STR00001##
S-OXIDES OF 2,3-DIARYL-2,3-DIHYDRO-4H-1,3-THIAZIN-4-ONES AND 2,3-DIARYL-1,3-THIAZEPAN-4-ONES AND METHODS FOR MAKING
A compound with the following general formula and a general method of making this compound are provided: R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.12, R.sup.13 and R.sup.14 are each independently selected from the group that includes hydrogen, halogen, nitro, cyano, amido, pyridyl, alkyl, aryl, alkoxy, cycloalkyl, heteroalkyl, heterocyclyl, aralkyl, heteroaryl and heteroaralkyl.
##STR00001##
Benzothia(di)azepine compounds and their use as bile acid modulators
The invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
CLASS OF MU-OPIOID RECEPTOR AGONISTS
The present invention provides a compound having the structure:
##STR00001##
or a pharmaceutically acceptable salt or ester thereof.
CLASS OF MU-OPIOID RECEPTOR AGONISTS
The present invention provides a compound having the structure:
##STR00001##
or a pharmaceutically acceptable salt or ester thereof.
3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: ##STR00001##
where R, L, X.sup.1, X.sup.2, X.sup.3, X.sup.4, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein.
3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formula I: ##STR00001##
where R, L, X.sup.1, X.sup.2, X.sup.3, X.sup.4, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein.